+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P06359(DCAF17 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P06359(DCAF17 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The DCAF17 antibody is a research tool developed to study the DCAF17 protein, a component of the CUL4-DDB1 E3 ubiquitin ligase complex. DCAF17 (DDB1- and CUL4-associated factor 17), also known as C2orf37. functions as a substrate receptor that recruits specific targets for ubiquitination and subsequent proteasomal degradation. It plays a critical role in cellular processes like DNA repair, cell cycle regulation, and organelle homeostasis. Mutations in the DCAF17 gene are linked to genetic disorders such as Woodhouse-Sakati syndrome (WSS) and 3-M syndrome, characterized by neuroendocrine abnormalities, developmental delays, and skeletal defects.

Antibodies against DCAF17 are primarily used in biomedical research to investigate its expression, localization, and interaction partners. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to analyze protein levels in tissues or cultured cells, particularly in studies exploring disease mechanisms. Monoclonal and polyclonal DCAF17 antibodies are commercially available, often validated for specificity using knockout cell lines or siRNA-mediated silencing. Recent studies also explore its potential role in cancer, as dysregulation of ubiquitination pathways is common in malignancies. These antibodies are crucial for deciphering DCAF17's physiological roles and its pathological implications in rare genetic diseases and broader human health contexts.